World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
110
Citations
54107
World Ranking
5477
National Ranking
541

Overview

Anas Younes is affiliated with AstraZeneca in the United Kingdom and has an extensive publication record in the fields of medicine, biochemistry, genetics, and molecular biology. Their research primarily focuses on pathology and forensic medicine, oncology, molecular biology, genetics, and pulmonary and respiratory medicine.

Their main research topics include:

  • Lymphoma Diagnosis and Treatment
  • Viral-associated cancers and disorders
  • Chronic Lymphocytic Leukemia Research
  • CAR-T cell therapy research
  • Lung Cancer Treatments and Mutations
  • Cancer Genomics and Diagnostics
  • Protein Degradation and Inhibitors

Younes has contributed extensively to several prominent scientific venues, including:

  • Blood
  • Blood Advances
  • Journal of Clinical Oncology
  • Leukemia & Lymphoma/Leukemia and Lymphoma
  • Haematologica

Their recent papers demonstrate a focus on lymphoma and cancer therapies, with notable publications such as:

  • Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups (2020, Blood Cancer Journal)
  • Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma (2020, Cancer Discovery)
  • Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial (2021, The Lancet Haematology)
  • OncoTree: A Cancer Classification System for Precision Oncology (2021, JCO Clinical Cancer Informatics)
  • Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies (2020, Blood Advances)

Anas Younes collaborates frequently with a group of researchers including:

  • Connie Lee Batlevi
  • Andrew D. Zelenetz
  • David J. Straus
  • Matthew J. Matasar
  • Alison J. Moskowitz

Best Publications

  • Guidelines for the use and interpretation of assays for monitoring autophagy

    Daniel J. Klionsky;Fabio C. Abdalla;Hagai Abeliovich;Robert T. Abraham

  • Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists

    Marilyn M. Li;Michael Datto;Eric J. Duncavage;Shashikant Kulkarni

  • Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

    Anas Younes;Ajay K. Gopal;Scott E. Smith;Stephen M. Ansell

  • Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

    Anas Younes;Nancy L Bartlett;John P Leonard;Dana A Kennedy

  • Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

    Anas Younes;Armando Santoro;Margaret Shipp;Pier Luigi Zinzani

  • Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome: An Evidence-Based Review

    Bertrand Coiffier;Arnold Altman;Ching-Hon Pui;Anas Younes

  • Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.

    Philippe Armand;Andreas Engert;Anas Younes;Michelle A Fanale

  • High Rate of Durable Remissions After Treatment of Newly Diagnosed Aggressive Mantle-Cell Lymphoma With Rituximab Plus Hyper-CVAD Alternating With Rituximab Plus High-Dose Methotrexate and Cytarabine

    Jorge E. Romaguera;Luis Fayad;Maria A. Rodriguez;Kristine R. Broglio

  • Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma

    Joseph M. Connors;Wojciech Jurczak;David J. Straus;Stephen M. Ansell

  • Phase II Study of Proteasome Inhibitor Bortezomib in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

    Andre Goy;Anas Younes;Peter McLaughlin;Barbara Pro

  • Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus.

    Mitchell S. Cairo;Bertrand Coiffier;Alfred Reiter;Anas Younes

  • Activation of the sphingomyelin signaling pathway in intact EL4 cells and in a cell-free system by IL-1 beta

    Shalini Mathias;Anas Younes;Chu-Cheng Kan;Irene Orlow

  • Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality

    Issa F. Khouri;Rima M. Saliba;Sergio A. Giralt;Ming Sheng Lee

  • Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma

    Anas Younes;Laurie H. Sehn;Peter Johnson;Pier Luigi Zinzani

  • Brentuximab Vedotin (SGN-35)

    Jessica Katz;John E. Janik;Anas Younes

  • Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma.

    I F Khouri;J Romaguera;H Kantarjian;J L Palmer

  • Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma

    Robert Chen;Ajay K. Gopal;Scott E. Smith;Stephen M. Ansell

  • AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer

    David Sanghyun Hong;Razelle Kurzrock;Youngsoo Kim;Richard Woessner

  • Risk Factors, Treatment, and Outcome of Central Nervous System Recurrence in Adults With Intermediate-Grade and Immunoblastic Lymphoma

    Koen van Besien;Chul S. Ha;Sandy Murphy;Peter McLaughlin

  • Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma.

    Peter McLaughlin;Fredrick B. Hagemeister;Jorge E. Romaguera;Andreas H. Sarris

Frequent Co-Authors

Luis Fayad
Luis Fayad The University of Texas MD Anderson Cancer Center
Peter McLaughlin
Peter McLaughlin The University of Texas MD Anderson Cancer Center
Fredrick B. Hagemeister
Fredrick B. Hagemeister The University of Texas MD Anderson Cancer Center
Andrew D. Zelenetz
Andrew D. Zelenetz Memorial Sloan Kettering Cancer Center
Larry W. Kwak
Larry W. Kwak City Of Hope National Medical Center
Craig H. Moskowitz
Craig H. Moskowitz University of Miami
David J. Straus
David J. Straus Memorial Sloan Kettering Cancer Center
Fernando Cabanillas
Fernando Cabanillas The University of Texas MD Anderson Cancer Center
L. Jeffrey Medeiros
L. Jeffrey Medeiros The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in alternative routes to a healthcare career, online degrees offer flexible options beyond the traditional medical school path. Many aspiring nurses and practitioners turn to programs that allow faster, more accessible advancement.

Nurses looking to earn a Bachelor of Science in Nursing might consider an rn to bsn online with no clinicals option, which eliminates on-site requirements for those with existing RN credentials. On the other hand, if you are aiming for advanced practice and leadership roles, the shortest online dnp program can be a direct pathway, especially for working professionals.

For even more convenience, some online dnp programs without clinicals remove or reduce in-person training, making it easier for those with experience to progress their skills. Meanwhile, entry-level students may benefit from enrolling in a accelerated lpn program online, jumpstarting their nursing careers in less time.

These varied online degree options highlight the evolving and expanding career pathways in medicine, making healthcare education more accessible than ever.

Best Scientists Citing Anas Younes

Trending Scientists

Recently Published Articles